Therapeutic potential of caffeic acid phenethyl ester (CAPE) in diabetes

Current Medicinal Chemistry

Volumn 25, Issue 37, 2018, Pages 4827-4836

  Pittalà, Valeria ^a   Salerno, Loredana ^a   Romeo, Giuseppe ^a   Acquaviva, Rosaria ^a   Di Giacomo, Claudia ^a   Sorrenti, Valeria ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Caffeic acid phenethyl ester; Diabetes; Diabetes induced complications; Inflammation; Nrf2; Oxidative stress; Polyphenols

Indexed keywords

CAFFEIC ACID PHENETHYL ESTER; FREE RADICAL; PROPOLIS; ANTIOXIDANT; CAFFEIC ACID DERIVATIVE; PHENETHYL ALCOHOL; POLYPHENOL;

ANTIDIABETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BIOLOGICAL ACTIVITY; DIABETES MELLITUS; HUMAN; IMMUNOMODULATION; NONHUMAN; OXIDATIVE STRESS; REVIEW; ANALOGS AND DERIVATIVES; ANIMAL; DIABETIC COMPLICATION; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECT; METABOLISM; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; CAFFEIC ACIDS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; OXIDATIVE STRESS; PHENYLETHYL ALCOHOL; POLYPHENOLS;

EID: 85030697624     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867324666161118120908     Document Type: Review

References (78)

1. Foulis, A.K.; C. L. Oakley lecture (1987). The pathogenesis of beta cell destruction in type I (insulin-dependent) diabetes mellitus. J. Pathol., 1987, 152(3), 141-148.
2. Clark, A.; Cooper, G.J.; Lewis, C.E.; Morris, J.F.; Willis, A.C.; Reid, K.B.; Turner, R.C. Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet, 1987, 2(8553), 231-234.
3. Hollander, M.H.; Paarlberg, K.M.; Huisjes, A.J. Gestational diabetes: a review of the current literature and guidelines. Obstet. Gynecol. Surv., 2007, 62(2), 125-136.
4. Collaboration, N.C.D.R.F. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet, 2016, 387, 1513-1530.
5. Morrish, N.J.; Wang, S.L.; Stevens, L.K.; Fuller, J.H.; Keen, H. Mortality and causes of death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia, 2001, 44(2), S14-21.
6. Pinto, A.; Tuttolomondo, A.; Di Raimondo, D.; Fernandez, P.; La Placa, S.; Di Gati, M.; Licata, G. Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot. Metabolism, 2008, 57(5), 676-682.
7. Eckel, R.H.; Wassef, M.; Chait, A.; Sobel, B.; Barrett, E.; King, G.; Lopes-Virella, M.; Reusch, J.; Ruderman, N.; Steiner, G.; Vlassara, H. Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: patho-genesis of atherosclerosis in diabetes. Circulation, 2002, 105(18), e138-143.
8. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature, 2001, 414(6865), 813-820.
9. Ceriello, A.; Testa, R.; Genovese, S.; Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications. Nutr. Met. Cardiovasc. Dis., 2016, 26(4), 285-292.
10. Vikram, A.; Tripathi, D.N.; Kumar, A.; Singh, S. Editorial. oxidative stress and inflammation in diabetic complications. Int. J. Endocrinol., 2014, 1, 1-2.
11. Giacco, F.; Brownlee, M. Oxidative stress and diabetic complications. Circul. Res., 2010, 107(9), 1058-1070.
12. Singh, D.K.; Winocour, P.; Farrington, K. Oxidative stress in early diabetic nephropathy: fueling the fire. Nat. Rev. Endocrinol., 2011, 7(3), 176-184.
13. Ueda, S.; Masutani, H.; Nakamura, H.; Tanaka, T.; Ueno, M.; Yodoi, J. Redox control of cell death. Antiox. Red. Sign., 2002, 4(3), 405-414.
14. Rochette, L.; Zeller, M.; Cottin, Y.; Vergely, C. Diabetes, oxidative stress and therapeutic strategies. Biochim. Biophys. Acta, 2014, 1840(9), 2709-2729.
15. Pitocco, D.; Tesauro, M.; Alessandro, R.; Ghirlanda, G.; Cardillo, C. Oxidative stress in diabetes: implications for vascular and other complications. Int. J. Mol. Sci., 2013, 14(11), 21525-21550.
16. Johansen, J.S.; Harris, A.K.; Rychly, D.J.; Ergul, A. Oxidative stress and the use of antioxidants in diabetes: Linking basic science to clinical practice. Cardiovasc. Diabetol., 2005, 4, 1-11.
17. Giugliano, D.; Ceriello, A.; Paolisso, G. Oxidative stress and diabetic vascular complications. Diabetes Care, 1996, 19(3), 257-267.
18. Maritim, A.C.; Sanders, R.A.; Watkins, J.B. Diabetes, oxidative stress, and antioxidants: A review. J. Biochem. Mol. Toxicol., 2003, 17(1), 24-38.
19. Esper, R.J.; Nordaby, R.A.; Vilarino, J.O.; Paragano, A.; Cacharron, J.L.; Machado, R.A. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc. Diabetol., 2006, 5, 1-18.
20. Bahadoran, Z.; Mirmiran, P.; Azizi, F. Dietary polyphenols as potential nutraceuticals in management of diabetes: a review. J. Diabetes Metab. Disord., 2013, 12(43), 1-9.
21. Georgoulis, M.; Kontogianni, M.D. Yiannakouris, N.; Mediterranean diet and diabetes: prevention and treatment. Nutrients, 2014, 6(4), 1406-1423.
22. Valdes, S.; Corpas, M.; Lena, M.; Rubio-Martin, E.; Mor-cillo, S.; Lima-Rubio, F.; Chicano, A.; Martin, G.; Porras, N.; Gomez-Zumaquero, J.; Soriguer, F.; Rojo-Martinez, G. Prevention of type 2 diabetes with Mediterranean diet. Preliminary results from the first year of intervention of the Egabro-Pizarra study. Diabetologia, 2012, 55, S359-S359.
23. Nabavi, S.M.; Daglia, M.; Sureda, A. Dietary polyphenols: well beyond the antioxidant capacity (Part I). Curr. Pharm. Biotechnol., 2014, 15(4), 297-297.
24. King, A.J.F. The use of animal models in diabetes research. Br. J. Pharmacol., 2012, 166(3), 877-894.
25. Kolb, H. Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab. Rev., 1987, 3(3), 751-778.
26. Viuda-Martos, M.; Ruiz-Navajas, Y.; Fernandez-Lopez, J.; Perez-Alvarez, J.A. Functional properties of honey, propolis, and royal jelly. J. Food Sci., 2008, 73(9), R117-124.
27. Ahmad, A.; Kaleem, M.; Ahmed, Z.; Shafiq, H. Therapeutic potential of flavonoids and their mechanism of action against microbial and viral infections-A review. Food Res. Int., 2015, 77, 221-235.
28. Gomez-Caravaca, A.M.; Gomez-Romero, M.; Arraez-Roman, D.; Segura-Carretero, A.; Fernandez-Gutierrez, A. Advances in the analysis of phenolic compounds in products derived from bees. J. Pharm. Biomedical Anal., 2006, 41(4), 1220-1234.
29. Izuta, H.; Shimazawa, M.; Tsuruma, K.; Araki, Y.; Mishima, S.; Hara, H. Bee products prevent VEGF-induced angiogenesis in human umbilical vein endothelial cells. BMC Complement. Alt. Med., 2009, 9(45), 1-10.
30. Tolba, M.F.; Azab, S.S.; Khalifa, A.E.; Abdel-Rahman, S.Z.; Abdel-Naim, A.B. Caffeic acid phenethyl ester, a promising component of propolis with a plethora of biological activities: A review on its anti-inflammatory, neuroprotective, hepatoprotective, and cardioprotective effects. Iubmb Life, 2013, 65(8), 699-709.
31. Murtaza, G.; Karim, S.; Akram, M.R.; Khan, S.A.; Azhar, S.; Mumtaz, A.; Bin Asad, M.H.H. Caffeic acid phenethyl ester and therapeutic potentials. Biomed. Res. Int., 2014, 1, 1-9.
32. Akyol, S.; Isik, B.; Altuntas, A.; Erden, G.; Cakmak, O.; Kursunlu, F.; Adam, B.; Akyol, O. Future opportunities in preventing ototoxicity: Caffeic acid phenethyl ester may be a candidate. Mol. Med. Rep., 2015, 12(3), 3231-3235.
33. Armutcu, F.; Akyol, S.; Ustunsoy, S.; Turan, F.F. Therapeutic potential of caffeic acid phenethyl ester and its anti-inflammatory and immunomodulatory effects. Exp. Ther. Med., 2015, 9(5), 1582-1588.
34. Murtaza, G.; Sajjad, A.; Mehmood, Z.; Shah, S.H.; Siddiqi, A.R. Possible molecular targets for therapeutic applications of caffeic acid phenethyl ester in inflammation and cancer. J. Food Drug Anal., 2015, 23(1), 11-18.
35. Akyol, S.; Ugurcu, V.; Altuntas, A.; Hasgul, R.; Cakmak, O.; Akyol, O. Caffeic Acid Phenethyl Ester as a Protective Agent against Nephrotoxicity and/or Oxidative Kidney Damage: A Detailed Systematic Review. Sci. World J., 2014, 1, 1-16.
36. Kokoszko-Bilska, A.; Stepniak, J.; Lewinski, A.; Kar-bownik-Lewinska, M. Protective antioxidative effects of caffeic acid phenethyl ester (CAPE) in the thyroid and the liver are similar to those caused by melatonin. Thyroid Res., 2014, 7, 1-5.
37. Hishikawa, K.; Nakaki, T.; Fujita, T. Oral flavonoid supplementation attenuates atherosclerosis development in apolipoprotein E-deficient mice. Arterioscl. Throm. Vasc. Biol., 2005, 25(2), 442-446.
38. Tsai, S.K.; Lin, M.J.; Liao, P.H.; Yang, C.Y.; Lin, S.M.; Liu, S.M.; Lin, R.H.; Chih, C.L.; Huang, S.S. Caffeic acid phenethyl ester ameliorates cerebral infarction in rats subjected to focal cerebral ischemia. Life Sci., 2006, 78(23), 2758-2762.
39. Gurel, A.; Armutcu, F.; Sahin, S.; Sogut, S.; Ozyurt, H.; Gulec, M.; Kutlu, N.O.; Akyol, O. Protective role of alpha-tocopherol and caffeic acid phenethyl ester on ischemia-reperfusion injury via nitric oxide and myeloperoxidase in rat kidneys. Clinica Chimica Acta, 2004, 339(1-2), 33-41.
40. Calikoglu, M.; Tamer, L.; Sucu, N.; Coskun, B.; Ercan, B.; Gul, A.; Calikoglu, I.; Kanik, A. The effects of caffeic acid phenethyl ester on tissue damage in lung after hindlimb ischemia-reperfusion. Pharmacol. Res., 2003, 48(4), 397-403.
41. Celik, O.; Turkoz, Y.; Hascalik, S.; Hascalik, M.; Cigremis, Y.; Mizrak, B.; Yologlu, S. The protective effect of caffeic acid phenethyl ester on ischemia-reperfusion injury in rat ovary. Eur. J. Obst. Gynecol. Reprod. Biol., 2004, 117(2), 183-188.
42. Parlakpinar, H.; Sahna, E.; Acet, A.; Mizrak, B.; Polat, A. Protective effect of caffeic acid phenethyl ester (CAPE) on myocardial ischemia-reperfusion-induced apoptotic cell death. Toxicol., 2005, 209(1), 1-14.
43. Ho, Y.J.; Lee, A.S.; Chen, W.P.; Chang, W.L.; Tsai, Y.K.; Chiu, H.L.; Kuo, Y.H.; Su, M.J. Caffeic acid phenethyl amide ameliorates ischemia/reperfusion injury and cardiac dysfunction in streptozotocin-induced diabetic rats. Cardiovasc. Diabetol., 2014, 13(98), 1-13.
44. Kassim, M.; Mansor, M.; Kamalden, T.A.; Shariffuddin, I.I.; Hasan, M.S.; Ong, G.; Sekaran, S.D.; Suhaimi, A.; Al-Abd, N.; Yusoff, K.M. Caffeic acid phenethyl ester (cape): scavenger of peroxynitrite in vitro and in sepsis models. Shock, 2014, 42(2), 154-160.
45. Da Cunha, F.M.; Duma, D.; Assreuy, J.; Buzzi, F.C.; Niero, R.; Campos, M.M.; Calixto, J.B. Caffeic acid derivatives: In vitro and in vivo anti-inflammatory properties. Free Rad. Res., 2004, 38(11), 1241-1253.
46. Kuo, Y.Y.; Jim, W.T.; Su, L.C.; Chung, C.J.; Lin, C.Y.; Huo, C.; Tseng, J.C.; Huang, S.H.; Lai, C.J.; Chen, B.C.; Wang, B.J.; Chan, T.M.; Lin, H.P.; Chang, W.S.W.; Chang, C.R.; Chuu, C.P. Caffeic acid phenethyl ester is a potential therapeutic agent for oral cancer. Int. J. Mol. Sci., 2015, 16(5), 10748-10766.
47. Yilmaz, H.R.; Uz, E.; Yucel, N.; Altuntas, I.; Ozcelik, N. Protective effect of caffeic acid phenethyl ester (CAPE) on lipid peroxidation and antioxidant enzymes in diabetic rat liver. J. Biochem. Mol. Toxicol., 2004, 18(4), 234-238.
48. Durmus, M.; Yilmaz, H.R.; Uz, E.; Ozcelik, N. The effect of caffeic acid phenethyl ester (CAPE) treatment on levels of MDA, NO and antioxidant enzyme activities in retinas of streptozotocin-induced diabetic rats. Turk. J. Med. Sci., 2008, 38(6), 525-530.
49. Okutan, H.; Ozcelik, N.; Yilmaz, H.R.; Uz, E. Effects of caffeic acid phenethyl ester on lipid peroxidation and antioxidant enzymes in diabetic rat heart. Clin. Biochem., 2005, 38(2), 191-196.
50. Schoenle, E.J.; Zenobi, P.D.; Torresani, T.; Werder, E.A.; Zachmann, M.; Froesch, E.R. Recombinant human insulin-like growth factor I (rhIGF I) reduces hyperglycaemia in patients with extreme insulin resistance. Diabetologia, 1991, 34(9), 675-679.
51. Acerini, C.L.; Clayton, K.L.; Hintz, R.; Baker, B.; Watts, A.; Holly, J.M.P.; Dunger, D.B. Serum insulin-like growth factor II levels in normal adolescents and those with insulin dependent diabetes mellitus. Clin. Endocrinol., 1996, 45(1), 13-19.
52. Park, S.H.; Min, T.S. Caffeic acid phenethyl ester ameliorates changes in IGFs secretion and gene expression in streptozotocin-induced diabetic rats. Life Sci., 2006, 78(15), 1741-1747.
53. Celik, S.; Erdogan, S.; Tuzcu, M. Caffeic acid phenethyl ester (CAPE) exhibits significant potential as an antidiabetic and liver-protective agent in streptozotocin-induced diabetic rats. Pharmacol. Res., 2009, 60(4), 270-276.
54. Lee, E.S.; Uhm, K.O.; Lee, Y.M.; Han, M.S.; Lee, M.S.; Park, J.M.; Suh, P.G.; Park, S.H.; Kim, H.S. CAPE (caffeic acid phenethyl ester) stimulates glucose uptake through AMPK (AMP-activated protein kinase) activation in skeletal muscle cells. Biochem. Biophys. Res. Comm., 2007, 361(4), 854-858.
55. Eid, H.M.; Vallerand, D.; Muhammad, A.; Durst, T.; Haddad, P.S.; Martineau, L.C.; Structural constraints and the importance of lipophilicity for the mitochondrial uncoupling activity of naturally occurring caffeic acid esters with potential for the treatment of insulin resistance. Biochem. Pharmacol., 2010, 79(3), 444-454.
56. Yucel, Y.; Celepkolu, T.; Kibrisli, E.; Kilinc, F.; Beyaz, C.; Aluclu,, M.U.; Basarili, M.K.; Ekinci, A. Protective effect of caffeic acid phenethyl ester in oxidative stress in diabetic rat sciatic nerve. Int. J. Pharmacol., 2012, 8(6), 577-581.
57. Chung, T.W.; Kim, S.J.; Choi, H.J.; Kwak, C.H.; Song, K.H.; Suh, S.J.; Kim, K.J.; Ha, K.T.; Park, Y.G.; Chang, Y.C.; Chang, H.W.; Lee, Y.C.; Kim, C.H. CAPE suppresses VEGFR-2 activation, and tumor neovascularization and growth. J. Mol. Med. (Berl), 2013, 91(2), 271-282.
58. Abduljawad, S.H.; El-Refaei, M.F.; El-Nashar, N.N. Protective and anti-angiopathy effects of caffeic acid phenethyl ester against induced type 1 diabetes in vivo. Int. Immunopharmacol., 2013, 17(2), 408-414.
59. Hassan, N.A.; El-Bassossy, H.M.; Mahmoud, M.F.; Fahmy, A. Caffeic acid phenethyl ester, a 5-lipoxygenase enzyme inhibitor, alleviates diabetic atherosclerotic manifestations: effect on vascular reactivity and stiffness. Chem. Biol. Interact., 2014, 213, 28-36.
60. Wang, X.; Stavchansky, S.; Zhao, B.; Bynum, J.A.; Kerwin, S.M.; Bowman, P.D. Cytoprotection of human endothelial cells from menadione cytotoxicity by caffeic acid phenethyl ester: the role of heme oxygenase-1. Eur. J. Pharmacol., 2008, 591(1-3), 28-35.
61. Wang, X.; Stavchansky, S.; Kerwin, S.M.; Bowman, P.D. Structure-activity relationships in the cytoprotective effect of caffeic acid phenethyl ester (CAPE) and fluorinated derivatives: effects on heme oxygenase-1 induction and antioxidant activities. Eur. J. Pharmacol., 2010, 635(1-3), 16-22.
62. Abraham, N.G.; Kappas, A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev., 2008, 60(2), 242-242.
63. Tiwari, S.; Ndisang, J.F. The heme oxygenase system and type-1 diabetes. Curr. Pharm. Des., 2014, 20(9), 1328-1337.
64. Salas, R.; Bibiloni, M.D.; Ramos, E.; Villarreal, J.Z.; Pons, A.; Tur, J.A.; Sureda, A. Metabolic Syndrome Prevalence among Northern Mexican Adult Population. PLoS One, 2014, 9(8), e105581.
65. Ohara, K.; Uchida, A.; Nagasaka, R.; Ushio, H.; Ohshima, T. The effects of hydroxycinnamic acid derivatives on adiponectin secretion. Phytomedicine, 2009, 16(2-3), 130-137.
66. Imai, M.; Kumaoka, T.; Hosaka, M.; Sato, Y.; Li, C.; Su-doh, M.; Tamada, Y.; Yokoe, H.; Saito, S.; Tsubuki, M.; Takahashi, N. Inhibitory effects of hydroxylated cinnamoyl esters on lipid absorption and accumulation. Bioorg. Med. Chem., 2015, 23(13), 3788-3795.
67. Juman, S.; Yasui, N.; Okuda, H.; Ueda, A.; Negishi, H.; Miki, T.; Ikeda, K. Caffeic acid phenethyl ester inhibits differentiation to adipocytes in 3T3-L1 mouse fibroblasts. Biol. Pharm. Bull., 2010, 33(9), 1484-1488.
68. Juman, S.; Yasui, N.; Okuda, H.; Ueda, A.; Negishi, H.; Miki, T.; Ikeda, K. Caffeic acid phenethyl ester suppresses the production of adipocytokines, leptin, tumor necrosis factor-alpha and resistin, during differentiation to adipocytes in 3T3-L1 cells. Biol. Pharm. Bull., 2011, 34(4), 490-494.
69. Vanella, L.; Tibullo, D.; Godos, J.; Pluchinotta, F.R.; Di Giacomo, C.; Sorrenti, V.; Acquaviva, R.; Russo, A.; Li Volti, G.; Barbagallo, I. Caffeic acid phenethyl ester regulates PPAR's Levels in Stem Cells-Derived Adipocytes. PPAR Res., 2016, 7359521, 1-13.
70. Bezerra, R.M.; Veiga, L.F.; Caetano, A.C.; Rosalen, P.L.; Amaral, M.E.; Palanch, A.C.; de Alencar, S.M. Caffeic acid phenethyl ester reduces the activation of the nuclear factor kappaB pathway by high-fat diet-induced obesity in mice. Metabolism, 2012, 61(11), 1606-1614.
71. Kurek-Gorecka, A.; Rzepecka-Stojko, A.; Gorecki, M.; Stojko, J.; Sosada, M.; Swierczek-Zieba, G. Structure and antioxidant activity of polyphenols derived from propolis. Molecules, 2014, 19(1), 78-101.
72. El-Awady, M.S.; El-Agamy, D.S.; Suddek, G.M.; Nader, M.A. Propolis protects against high glucose-induced vascular endothelial dysfunction in isolated rat aorta. J. Physiol. Biochem., 2014, 70(1), 247-254.
73. Boisard, S.; Le Ray, A.M.; Gatto, J.; Aumond, M.C.; Blanchard, P.; Derbre, S.; Flurin, C.; Richomme, P. Chemical composition, antioxidant and anti-AGEs activities of a French poplar type propolis. J. Agric. Food. Chem., 2014, 62(6), 1344-1351.
74. Al Ghamdi, A.A.; Badr, G.; Hozzein, W.N.; Allam, A.; Al-Waili, N.S.; Al-Wadaan, M.A.; Garraud, O. Oral supplementation of diabetic mice with propolis restores the proliferation capacity and chemotaxis of B and T lymphocytes towards CCL21 and CXCL12 by modulating the lipid profile, the pro-inflammatory cytokine levels and oxidative stress. BMC Immunol., 2015, 16(54), 1-14.
75. Hozzein, W.N.; Badr, G.; Al Ghamdi, A.A.; Sayed, A.; Al-Waili, N.S.; Garraud, O. Topical application of propolis en-en- hances cutaneous wound healing by promoting tgf-beta/smad-mediated collagen production in a streptozotocin-induced type i diabetic mouse model. Cell. Physiol. Biochem., 2015, 37(3), 940-954. hances
76. Henshaw, F.R.; Bolton, T.; Nube, V.; Hood, A.; Veldhoen, D.; Pfrunder, L.; McKew, G.L.; MacLeod, C.; McLennan, S.V.; Twigg, S.M. Topical application of the bee hive protectant propolis is well tolerated and improves human diabetic foot ulcer healing in a prospective feasibility study. J. Diabetes Complicat., 2014, 28(6), 850-857.
77. Zhao, L.; Pu, L.; Wei, J.; Li, J.; Wu, J.; Xin, Z.; Gao, W.; Guo, C. Brazilian green propolis improves antioxidant function in patients with type 2 diabetes mellitus. Int. J. Environ Res. Public Health, 2016, 13(5), 1-9.
78. ClinicalTrials.gov. Available at: A service of the U.S. National Institutes of Health https://clinicaltrials.gov/ct2/show/NCT02050334.